WGS GeneDx Holdings Corp.
Services-Health Services · Nasdaq · SEC CIK 1818331 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.6%
TTM net income YoY-5,431.2%
TTM EPS YoY-3,518.2%
Revenue 3-yr CAGR30.7%
Net income 3-yr CAGR—
Margins
Gross margin68.7%
Operating margin-21.6%
Net margin-24.1%
FCF margin-22.0%
EBITDA margin-19.0%
Returns
ROE-41.4%
ROA-21.8%
ROIC (approx.)-29.0%
Asset turnover0.90x
Leverage & solvency
Liabilities / assets53.5%
Debt / equity0.60x
Current ratio4.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-7.1%
Payout ratio—
Capex / revenue5.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $123.10M | $114.44M | $102.25M | $120.99M | $116.74M | $102.69M | $87.11M | $95.64M |
| Cost of revenue | $37.04M | $36.20M | $34.04M | $36.72M | $32.22M | $31.79M | $28.64M | $29.43M |
| Gross profit | $86.06M | $78.24M | $68.21M | $84.27M | $84.53M | $70.90M | $58.48M | $66.20M |
| R&D expense | $17.37M | $19.66M | $19.80M | $24.54M | $19.83M | $15.08M | $12.58M | $11.59M |
| SG&A expense | $79.12M | $76.04M | $74.59M | $46.83M | $67.95M | $46.86M | $50.45M | $28.14M |
| Operating income | -$10.43M | -$17.45M | -$57.47M | -$14.23M | -$3.25M | $8.96M | -$4.55M | $8.81M |
| Pretax income | -$12.30M | -$18.26M | -$62.42M | -$18.23M | -$7.39M | $10.56M | -$6.08M | $5.41M |
| Income tax | $26,000 | -$518,000 | $897,000 | -$564,000 | $247,000 | -$246,000 | $447,000 | -$24,000 |
| Net income | -$12.33M | -$17.74M | -$63.32M | -$17.67M | -$7.63M | $10.81M | -$6.53M | $5.44M |
| EBITDA | -$7.13M | -$14.36M | -$54.77M | -$11.44M | -$851,000 | $11.26M | -$2.35M | $10.83M |
| EPS (basic) | -0.41 | -0.60 | -2.16 | — | -0.27 | 0.38 | -0.23 | — |
| EPS (diluted) | -0.41 | -0.60 | -2.16 | — | -0.27 | 0.36 | -0.23 | — |
| Weighted avg. shares (diluted) | 29.88M | 29.71M | 29.34M | — | 28.80M | 29.75M | 28.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $96.14M | $60.32M | $93.92M | $105.00M | $96.96M | $75.11M | $100.69M | $86.20M |
| Short-term investments | $73.98M | $72.23M | $76.76M | $66.28M | $59.11M | $60.44M | $59.46M | $55.97M |
| Receivables | $92.13M | $83.61M | $76.93M | $74.37M | $60.94M | $48.03M | $45.98M | $37.63M |
| Inventory | $21.70M | $17.82M | $12.24M | $13.95M | $10.57M | $11.93M | $12.66M | $10.65M |
| Current assets | $296.89M | $246.36M | $270.63M | $268.29M | $237.58M | $204.84M | $225.82M | $197.97M |
| PP&E, net | $53.53M | $54.32M | $50.12M | $45.69M | $42.42M | $40.12M | $36.38M | $32.89M |
| Goodwill | $1.64M | $1.64M | $1.64M | $13.52M | $12.80M | $12.93M | — | $0 |
| Intangibles | $137.73M | $141.35M | $144.97M | $168.48M | $172.59M | $176.69M | $155.09M | $158.60M |
| Total assets | $526.48M | $481.49M | $506.30M | $523.71M | $493.90M | $463.86M | $446.43M | $419.38M |
| Current liabilities | $71.40M | $74.63M | $87.64M | $108.91M | $87.62M | $71.41M | $69.54M | $54.82M |
| Short-term debt | $0 | $0 | $0 | $4.54M | $1.23M | $1.22M | $1.22M | $1.21M |
| Long-term debt | $146.23M | $96.84M | $96.73M | $48.18M | $51.58M | $51.68M | $51.79M | $51.91M |
| Total debt | $146.23M | $96.84M | $96.73M | $52.72M | $52.81M | $52.91M | $53.01M | $53.12M |
| Total liabilities | $281.80M | $237.26M | $252.18M | $215.53M | $201.64M | $186.73M | $189.03M | $174.13M |
| Shareholders' equity | $244.69M | $244.22M | $254.12M | $308.18M | $292.26M | $277.13M | $257.40M | $245.25M |
| Net debt | $50.09M | $36.52M | $2.81M | -$52.28M | -$44.15M | -$22.20M | -$47.68M | -$33.08M |
| Shares outstanding | 29.95M | 29.80M | 29.67M | 29.25M | 28.89M | 28.71M | 28.53M | 28.02M |
| Cash flow statement | ||||||||
| Operating cash flow | -$10.60M | -$28.98M | -$32.41M | -$3.09M | $15.77M | $10.42M | $10.18M | -$3.18M |
| Capital expenditure | $5.22M | $10.11M | $6.45M | $4.35M | $6.17M | $2.37M | $6.13M | $3.05M |
| Free cash flow | -$15.82M | -$39.09M | -$38.86M | -$7.44M | $9.60M | $8.05M | $4.05M | -$6.23M |
| Investing cash flow | -$7.42M | -$5.63M | -$17.25M | -$11.07M | -$4.69M | -$36.35M | -$9.41M | -$519,000 |
| Financing cash flow | $53.84M | $1.00M | $38.59M | $23.19M | $10.77M | $346,000 | $13.72M | $31.02M |
| Depreciation & amortization | $3.30M | $3.10M | $2.70M | $2.80M | $2.40M | $2.30M | $2.20M | $2.02M |
| Stock-based compensation | $8.25M | $6.34M | $9.00M | $9.78M | $10.59M | $7.81M | $3.98M | $2.85M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.